Patrick Eimerman
Company: Saga Diagnostics AB
Job title: Vice President - Business Development & Partnerships
Seminars:
Increasing Access to ctDNA Assessment for Biomarker Discovery, Development, & CDx Programs 12:45 pm
A disruptive, low-cost approach to MRD detection and quantification using WGS and a proprietary dPCR platform Structural Variants (SVs) are the ideal pan-cancer biomarker for determining MRD status using dPCR Increased analytical sensitivity demonstrates improved clinical performanceRead more
day: Day Two Track A